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Abstract 
Introduction: The research of abnormal toxicity and locally irritating effect of the drug Furacilin, concentrate for the 
preparation of a solution for local and external use in comparison with the drug Furacilin, tablets for the preparation of the 
solution, was carried out.  
Objectives of the study: To determine the abnormal toxicity and locally irritating effect of the drug Furacilin in the Draize 
test (OECD No. 405). 
Methods: Abnormal toxicity was performed according to the requirements of the State Pharmacopoeia of the Russian 
Federation (OFS.1.2.4.0004.15). The studied drugs were administered intraperitoneal volume of 0.5 ml (dose 25 mg/kg) at 
a rate of 0.1 ml per second. The Draize test was performed by instillation into the conjunctival sac of rabbit medicals at a 
concentration of 0.02% with a volume of 0.1 ml. 
Results: After a single intraperitoneal administration of the studied drugs at a dose of 25 mg/kg, within 48 hours from the 
moment of their introduction, the death of animals was not observed in any of the experimental groups. 
After instillation of 0.02% solutions of 0.1 ml of the studied drugs to rabbits, and subsequent observation after 1, 24, 48 and 
72 hours of changes in the conjunctiva, cornea and iris, chemosis was not registered. The number of points in all 
parameters, in all experimental groups, did not exceed 0 points. 
Conclusion: The obtained data indicate that Furacilin, a concentrate for the preparation of a solution for local and external 
use 4 mg/ml in its parameters of Toxicological safety and the absence of local irritant action at the site of application, 
comparable to the drug comparison Furacilin, tablets for the preparation of a solution for local and external use 20 mg. 
Keywords: Nitrofural, Furacilin Tablets, Furacilin Concentrate for the Preparation of a Solution for Local and External 
Use, Abnormal Toxicity. 
 
Introduction 
Nitrofural (Furacilin) belongs to the group of 
nitrofurans. It has antimicrobial action. It is used as a 
liquid for washing and cleansing wounds, due to its 
antiseptic properties it slows down or stops the growth 
of microbial flora and the growth of fungi [7, 8, 15, 
27, 28].The mechanism of action of nitrofurans is not 
fully studied. Nitrofurans are prodrugs that are 
activated by specific enzymes. Antibacterial activity 
of nitrofurans is derived from reductive metabolism of 
the nitro group catalyzed by nitroreductase-Zoi [12, 
21, 25, 24, 29, 30]. Nitrofurans can be transformed by 
releasing nitric oxide to form toxic peroxynitrite and 
other oxidized derivatives [14, 26, 31]. Taking into 
account the formation of nitric oxide from nitrofurans, 
as well as existing antibacterial nitric oxide donors, 
there is an assumption that the antibacterial effect of 
nitrofurans may be due to the activity of nitric oxide 
[12, 6, 32, 33].We studied the effects of nitrofuran 
(nitrofural), of furacilin, nitrofurantoin, nifuroxazide 
and donors of nitric oxide - sodium nitro-prusside and 
isosorbide Mononitrate on the formation of biofilms 
of Pseudomonas aeruginosa PAO1 and Burkholderia 
cenocepacia 370. All compounds have been shown to 
increase the ability of these pathogenic bacteria to 
form biofilms at concentrations that do not inhibit 
bacterial growth in experimental conditions [22]. 
Antimicrobial activity of nitrofurans in vitro in 
relation to some pathogens correlates with the activity 
of drugs in vivo on experimental models. The activity 
of nitrofurans (nitrofurantoin, nitrofurazone, 
furazolidone, furaltadone, etc.) is shown in 
experiments on mice in infections caused by 
enterobacteria, vibrions, staphy-lococci and 
streptococci; in experiments on chickens and turkeys 
in infections caused by Salmonella, staphylococci, 
coccidia. In experiments on mice with infection 
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caused by pneumococcus, the drugs were not active 
[11, 34]. 
The mechanism of nitrofurans action on the 
microbial cell consists of several factors. The drugs 
are oxygen acceptors and disrupt the process of 
cellular respiration; nitrofurans inhibit the activity of a 
number of respiratory enzymes of the cell (pyruvate 
oxidase, glutathione reductase, aldehyde 
dehydrogenase). The drugs are eposed intracellular 
transformation: the process of restoring the nitrogroup 
under the action of bacterial flavoproteins. As a result, 
metabolites of nitrofurans are formed, which have a 
cytotoxic effect. Cytotoxic action of nitrofurans in 
combination with violation of cellular respiration 
causes the activity of some drugs (furazolidone, 
nifuratel) in high concentrations not only in the 
presence of bacteria and protozoa (Trichomonas, 
Giardia, dysentery amoeba), but also in respect of 
fungi, including the genus Candida. The drugs inhibit 
the biosynthesis of microbial DNA and extent RNA 
less. The mechanism of action of nitrofurans can not 
be considered fully deciphered, but it is specific only 
for drugs in this group. That is why nitrofurans are 
active against most strains of bacteria resistant to 
antimicrobial agents of other chemical classes [2, 12]. 
Furacilin affects various gram-positive and gram-
negative bacteria: staphylococci (Staphylococcus 
spp.), Streptococcus (Streptococcus spp.), dysentery 
and E. coli (Shigella dysen-teria spp., Shigella flexneri 
spp., Shigella boydii spp., Shigella sonnei spp., 
Escherichia coli), Salmonella (Salmonella spp), 
pathogens of paratyphoid and gas gangrene 
(Clostridium perfringens), Giardia, Trichomonas, 
large viruses, etc. 
It is effective at resistance of microorganisms to 
other antimicrobial agents (not from the group of 
nitrofuran derivatives). It inhibits the vital activity of 
fungal flora. The mechanism of action is based on the 
restoration of 5-nitrogroup microbial flavoproteins to 
form reactive amino derivatives that can cause 
changes in proteins (including ribosomal) and other 
macromolecules, leading to the death of cells of 
pathological microorganisms. Due to the fact that drug 
resistance develops slowly and does not reach a high 
degree, nitrofural is of particular importance in 
medical practice [1]. 
Despite the rapid development of experimental 
pharmacology [9, 16], the spread of recombinant 
drugs [23], drug design methods, which allow to 
create a highly selective drugs [17, 19], classical drugs 
[18, 10, 4, 11], including the nitrofuran derivate - 
furacilin, remain highly important. 
The research of safety and pharmacological 
activity of the new drugs [2, 3, 5, 12, 13, 20, 18] plays 
a special role in providing the pharmaceutical market 
with new quality products. 
To register the drug Furacilin, concentrate for the 
preparation of a solution for local and external use 4 
mg/ml, which is a generic drug for the time-decided to 
use in the Russian drug Furacilin, tablets for the 
preparation of a solution for local and external use 20 
mg, containing in its composition the active 
substance-nitrofural. 
Objectives of the Study 
The research of abnormal toxicity and local irritant 
effect in the Draize test (OECD No. 405) of the drug 
Furacilin, concentrate for preparation of solution for 
local and external use 4 mg/ml in comparison with the 
drug Furacilin tablets for preparation of solution for 
local and external use 20 mg. 
Materials and Methods 
Experiments were conducted on white laboratory 
mice and chinchilla rabbits. For the study were taken 
animals without external signs of the disease, which 
had a quarantine. Ethical principles of treatment of 
laboratory animals were observed in accordance with 
the "European Convention for the protection of 
vertebrates used for experimental and other scientific 
purposes. CETS No. 123". 
The experiment on the study of abnormal toxicity 
included the following groups: the first – Furacilin, 
concentrate for the preparation of a solution for local 
and external use 4 mg/ml (n=10); the second – 
Furacilin (artificially aged), concentrate for the 
preparation of a solution for local and external use 4 
mg/ml (n=10); the third – Furacilin, concentrate for 
preparation of solution for local and external 
application of 20 mg/ml (n=10); the fourth – Furacilin 
(artificially aged), concentrate for preparation of 
solution for local and external application of 20 mg/ml 
(n=10); the fifth– Furacilin, tablets for preparation of 
solution for local and external application of 20 mg 
(n=10). 
The experiment for the Draize test included the 
following groups: the first – Furacilin, concentrate for 
the preparation of a solution for local and external use 
4 mg/ml (n=10); the second – Furacilin, concentrate 
for the preparation of a solution for local and external 
use 20 mg/ml (n=10); the third – Furacilin, tablets for 
preparation of a solution for local and external 
application of 20 mg (n=10). 
The research of the abnormal toxicity was 
performed according to the requirements of the State 
Pharmacopoeia of the Russian Federation 
(FFS.1.2.4.0004.15). The studied drugs were 
administered intraperitoneal volume of 0.5 ml (dose 
25 mg/kg) at a rate of 0.1 ml per second.  
The preparation of doses was carried out the 
following way: Furacilin, concentrate for the 
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preparation of a solution for local and external use 4 
mg/ml: 0.125 ml of the concentrate solution was 
adjusted to 0.5 ml with water for injection; Furacilin, 
concentrate for preparation of solution for local and 
external use 20 mg/ml: 0,025 ml of the concentrate 
was adjusted to 0.5 ml with water for injection; 
Furacilin tablets for preparation of solution for local 
and external use 1 tablet (20 mg), was dissolved in 20 
ml of water for injection. 
Monitoring of animals was carried out within 48 
hours from the date of administration of drugs. The 
drugs were considered to have passed the test if none 
of the experimental animals died within the prescribed 
period of observation. 
When studying the locally irritating effect on the 
conjunctiva of the rabbit’s eye, the studied drugs and 
the comparison drug were instilled into the 
conjunctival sac at a concentration of 0.02% with a 
volume of 0.1 ml. 
Experiments began with 1 animal in each group, 
then the experiments continued on 2 animals in each 
group. 
After the instillation of the studied drugs, the eye 
condition was assessed 1, 24, 48 and 72 hours after 
the use of the tested drugs.  
Guidelines (conjunctiva, cornea and iris) the 
Guidelines presented in the OECD guidelines for the 
testing of chemicals test No. 405: acute eye 
irritation/corrosion. 
Results 
Studies have shown that after a single 
intraperitoneal administration of the studied drugs at a 
dose of 25 mg/kg, within 48 hours from their 
introduction, the death of animals was not observed in 
any of the experimental groups. 
The studies showed that after instillation of 0.02% 
solutions of the studied preparations with a volume of 
0.1 ml to rabbits, and subsequent observation after 1, 
24, 48 and 72 hours of changes in the conjunctiva, 
cornea and iris, chemosis was not registered. The 
number of points in all parameters in all experimental 
groups did not exceed 0 points (table 1, Annex 2). The 
state of the controled eyes in all experimental groups 
was unchanged and corresponded to the state of intact 
eyes. 
 
 
Figure-1: Controled eye of the rabbit, after 
instillation of Furacilin, concentrate for preparation 
of solution for local and external use 4 mg/ml, 72 
hours after the instillation 
 
Figure-2: Controlled eye of the rabbit after 
instillation of Furacilin, concentrate for preparation 
of solution for local and external use 20 mg/ml, 72 
hours after the instillation 
 
Figure-3: The controlled eyes of rabbits after 
instillation Furacilin tablets for preparation of 
solution for local and external use 20 mg, through 
72 hours after the instillation 
On the basis of the study, it was concluded that the 
drugs: Furacilin, concentrate for the preparation of a 
solution for local and external use 4 mg/ml, Furacilin, 
concentrate for the preparation of a solution for local 
and external use 20 mg/ml in a concentration of 
0.02% do not have a locally irritating effect. 
Thus, drugs Furacilin, concentrate for preparation 
of solution for local and external use 4 mg/ml (part 1), 
Furacilin, concentrate for preparation of solution for 
local and external use 20 mg/ml and Furacilin tablets 
for preparation of solution for local and external use 
20 mg according to the study, possess good 
tolerability and do not have a local irritating effect. 
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Discussion 
Investigation of abnormal toxicity of drugs 
Furacilin, concentrate for preparation of a solution for 
local and external use 4 mg/ml, Furacilin (artificially 
aged), concentrate for preparation of a solution for 
local and external use 4 mg/ml, Furacilin, concentrate 
for preparation of a solution for local and external use 
20 mg/ml, Furacilin (artificially Aged), concentrate 
for the preparation of a solution for local and external 
use 20 mg/ml and a comparison drug Furacilin, tablets 
for the preparation of a solution for local and external 
use 20 mg, was carried out on males and females of 
white laboratory mice. The drugs were administered 
in a volume of 0.5 ml (dose 25 mg/kg) 
intraperitoneally at a rate of 0.1 ml per second. The 
subsequent observation period was 48 h. It was 
established that the investigated drugs and the 
reference drug in the dose of 25 mg/kg did not cause 
death of animals. 
The study of the local irritant effect of Furacilin, a 
concentrate for the preparation of a solution for local 
and external use 4 mg/ml, Furacilin, a concentrate for 
the preparation of a solution for local and external use 
20 mg/ml, and a comparison drug Furacilin, tablets for 
the preparation of a solution for local and external use 
20 mg, was conducted male rabbits. Preparations in 
the form of 0.02% solutions were installed in the 
conjunctival sac in a volume of 0.1 ml. 
Observations and assessment of the eye condition 
were carried out 1, 24, 48 and 72 hours after the use of 
the tested drugs. It was found that the studied drugs 
and the comparison drug when instilled into the 
conjunctival sac in the form of 0.02% solutions in the 
amount of 0.1 ml do not cause chemosis, damage or 
changes in the conjunctiva, cornea and iris in 1, 24, 48 
and 72 hours.  
Conclusion 
According to the results of the research, it was 
concluded that the studied drugs do not have a toxic 
effect during the test in abnormal toxicity and do not 
have a locally irritating drift in the Draize test (OECD 
guidelines for testing chemicals test No. 405: acute 
irritation/corrosion) 
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